We studied the circulating PD‐L1–specific CAR‐T cells in a patient with non‐small cell lung cancer. Circulating PD‐L1–specific CAR‐T cells accounted for 3.30% of the patient’s peripheral blood T cells detected by FACS in the first follow‐up (Day +29), and a chest CT scan showed subtle shrinkage of tumors (stable disease). However, the patient was immediately transferred to the ICU on Day +47 because he deteriorated quickly into respiratory failure in three days. This case might represent a unique clinical manifestation of solitary organ damage secondary to PD‐L1–specific CAR‐T cell therapy.
All Keywords
【저자키워드】 IL‐6, NSCLC, pulmonary toxicity, CAR‐T, PD‐L1,
【저자키워드】 IL‐6, NSCLC, pulmonary toxicity, CAR‐T, PD‐L1,